Markus Moehler

List of Publications by Year
in descending order

58 papers	8,338 citations	172457 29 h-index	138484 58 g-index
61 all docs	61 docs citations	61 times ranked	8687 citing authors

#	Article	IF	Citations
1	Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet, The, 2019, 393, 1948-1957.	13.7	1,494
2	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2014, 15, 1065-1075.	10.7	1,479
3	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet, The, 2021, 398, 27-40.	13.7	1,237
4	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	13.7	984
5	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncology, The, 2013, 14, 490-499.	10.7	740
6	Chemotherapy for advanced gastric cancer. The Cochrane Library, 2017, 2017, CD004064.	2.8	662
7	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. Journal of Clinical Oncology, 2021, 39, 966-977.	1.6	122
8	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clinical Cancer Research, 2017, 23, 5671-5678.	7.0	121
9	International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer, 2015, 18, 550-563.	5.3	79
10	FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. British Journal of Cancer, 2021, 124, 587-594.	6.4	79
11	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. European Journal of Cancer, 2016, 59, 160-170.	2.8	78
12	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treatment Reviews, 2018, 66, 104-113.	7.7	78
13	Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Therapy, 2001, 8, 158-167.	4.6	68
14	Immunotherapy in Gastric Cancer. Current Oncology, 2022, 29, 1559-1574.	2.2	65
15	Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Annals of Oncology, 2020, 31, 228-235.	1.2	60
16	VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.8	57
17	Molecular landscape of esophageal cancer: implications for early detection and personalized therapy. Annals of the New York Academy of Sciences, 2018, 1434, 342-359.	3.8	56
18	Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. BMC Cancer, 2016, 16, 699.	2.6	54

#	Article	IF	Citations
19	Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells. Cancer Gene Therapy, 2003, 10, 477-480.	4.6	49
20	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. Journal of Clinical Oncology, 2021, 39, 4009-4019.	1.6	45
21	Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. Targeted Oncology, 2019, 14, 505-525.	3.6	40
22	Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. OncoTargets and Therapy, 2017, Volume 10, 2389-2401.	2.0	36
23	VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World Journal of Gastroenterology, 2008, 14, 4156.	3.3	36
24	Multimodal treatment of gastric cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 965-981.	2.4	35
25	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Targeted Oncology, 2016, 11, 469-477.	3.6	34
26	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. Critical Reviews in Oncology/Hematology, 2018, 130, 13-26.	4.4	34
27	Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. Gastric Cancer, 2017, 20, 904-912.	5.3	33
28	Perioperative chemotherapy with or without epidermal growth factor receptorÂblockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). European Journal of Cancer, 2018, 93, 119-126.	2.8	33
29	Activation of the human immune system via tollâ€like receptors by the oncolytic parvovirus Hâ€1. International Journal of Cancer, 2013, 132, 2548-2556.	5.1	32
30	Gastric cancer in autoimmune gastritis: A caseâ€control study from the German centers of the staR project on gastric cancer research. United European Gastroenterology Journal, 2020, 8, 175-184.	3.8	30
31	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. European Journal of Cancer, 2022, 164, 18-29.	2.8	27
32	Supportive evidence for <scp>FOXP</scp>1,<scp>BARX</scp>1, and <scp>FOXF</scp>1 as genetic risk loci for the development of esophageal adenocarcinoma. Cancer Medicine, 2015, 4, 1700-1704.	2.8	26
33	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. Journal of Hepatology, 2020, 73, 1109-1117.	3.7	25
34	Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. BMC Cancer, 2019, 19, 55.	2.6	24
35	Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1. Frontiers in Oncology, 2014, 4, 92.	2.8	22
36	Evidence for <scp>PTGER</scp>4,<scp>PSCA</scp>, and <scp>MBOAT</scp>7 as risk genes for gastric cancer on the genome and transcriptome level. Cancer Medicine, 2018, 7, 5057-5065.	2.8	22

#	Article	IF	Citations
37	The Barrettâ€associated variants at <scp>GDF</scp>7 and <scp>TBX</scp>5 also increase esophageal adenocarcinoma risk. Cancer Medicine, 2016, 5, 888-891.	2.8	21
38	Virotherapy Research in Germany: From Engineering to Translation. Human Gene Therapy, 2017, 28, 800-819.	2.7	19
39	Virotherapy in Germanyâ€"Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. Viruses, 2021, 13, 1420.	3.3	19
40	(Neo)adjuvant Strategies of Advanced Gastric Carcinoma: Time for a Change?. Digestive Diseases, 2004, 22, 345-350.	1.9	18
41	Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. Anti-Cancer Drugs, 2003, 14, 645-650.	1.4	17
42	Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. OncoTargets and Therapy, 2013, 6, 1119.	2.0	16
43	Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. Anti-Cancer Drugs, 2003, 14, 79-85.	1.4	14
44	Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071). Cancer Chemotherapy and Pharmacology, 2018, 82, 733-739.	2.3	13
45	Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing. Frontiers in Oncology, 2019, 9, 425.	2.8	13
46	Relevance of liverâ€limited disease in metastatic colorectal cancer: Subgroup findings of the FIREâ€3/AIO KRK0306 trial. International Journal of Cancer, 2018, 142, 1047-1055.	5.1	12
47	Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. International Journal of Clinical Oncology, 2014, 19, 288-296.	2.2	11
48	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). OncoImmunology, 2020, 9, 1806680.	4.6	11
49	Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. Journal of Cancer Research and Clinical Oncology, 2015, 141, 515-522.	2.5	10
50	Comparison of a 48-Hour Infusion of 5-Fluorouracil without Folinic Acid with 24-Hour Folinic Acid/5-Fluorouracil in Patients with Metastatic Colorectal Cancer Refractory to Bolus Folinic Acid/5-Fluorouracil. Chemotherapy, 2003, 49, 85-89.	1.6	8
51	VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer, 2014, 14, 476.	2.6	8
52	The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. Journal of Clinical Medicine, 2021, 10, 2732.	2.4	8
53	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (<scp>LICC</scp>, <scp>CELIM</scp>, <scp>FIRE</scp>â€3). International Journal of Cancer, 2022, 150, 1341-1349.	5.1	6
54	Moguntinonesâ€"New Selective Inhibitors for the Treatment of Human Colorectal Cancer. Molecular Cancer Therapeutics, 2014, 13, 1399-1409.	4.1	5

#	Article	IF	Citations
55	Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naÃ¯ve advanced or metastatic esophagogastric cancer. Gastric Cancer, 2017, 20, 358-367.	5.3	4
56	Loss ofLLGL1Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-12.	1.9	4
57	A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210754.	3.2	4
58	CXCR4 and hif-1Î± as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset. Acta OncolÃ³gica, 2021, 60, 1543-1547.	1.8	1